var data={"title":"Cephalexin: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Cephalexin: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/5854?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=cephalexin-patient-drug-information\" class=\"drug drug_patient\">see &quot;Cephalexin: Patient drug information&quot;</a> and <a href=\"topic.htm?path=cephalexin-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Cephalexin: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F148610\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Daxbia;</li>\n      <li>Keflex</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F148611\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Apo-Cephalex;</li>\n      <li>Dom-Cephalexin;</li>\n      <li>Keflex;</li>\n      <li>PMS-Cephalexin;</li>\n      <li>Teva-Cephalexin</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F148629\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antibiotic, Cephalosporin (First Generation)</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F148613\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Usual dosage range:</b> Oral: 250 to 1,000 mg every 6 hours or 500 mg every 12 hours (maximum: 4 g/day)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Indication-specific dosing:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Cellulitis (nonpurulent)/erysipelas, mild (alternative agent): </b>Oral: 500 mg 4 times daily for at least 5 days (duration should be extended if not resolved/slow response) (IDSA [Stevens 2014])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Cystitis, uncomplicated (alternative agent):</b> Oral: 500 mg every 12 hours for 5 to 7 days (Hooton 2018)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Endocarditis, prophylaxis (dental or invasive respiratory tract procedures; alternative agent) (off-label use):</b> Oral: 2 g 30 to 60 minutes prior to procedure. <b>Note:</b> American Heart Association (AHA) guidelines recommend prophylaxis only in patients undergoing invasive procedures and in whom underlying cardiac conditions may predispose to a higher risk of adverse outcomes should infection occur (AHA [Wilson 2007]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Impetigo or ecthyma:</b> Oral: 250 to 500 mg 4 times daily for 7 days.<b> Note:</b> Not an appropriate agent if MRSA is suspected or confirmed (Baddour 2018; IDSA [Stevens 2014]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Pharyngitis, streptococcal (alternative agent):</b> Oral: 500 mg every 12 hours for 10 days (IDSA [Shulman 2012])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Prosthetic joint infection (off-label use): </b> Oral: Treatment (following pathogen-specific IV therapy in patients undergoing 1-stage exchange or debridement with retention of prosthesis).<b> Note:</b> Duration ranges from a minimum of 3 months to indefinitely, depending on patient-specific factors (Berbari 2018):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Staphylococci (methicillin-susceptible): 500 mg every 6 to 8 hours. For the first 3 to 6 months of therapy, combine with rifampin (Berbari 2018; IDSA [Osmon 2013]).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Streptococci, beta-hemolytic (alternative agent): 500 mg every 6 to 8 hours (Berbari 2018; IDSA [Osmon 2013])</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Cutibacterium </i>spp (alternative agent): 500 mg every 6 to 8 hours (IDSA [Osmon 2013]; Kanafani 2018)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F148624\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=cephalexin-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Cephalexin: Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Usual dosage range:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children &gt;1 year and Adolescents &lt;15 years: Oral: 25 to 100 mg/kg/day in divided doses every 6 to 8 hours (maximum: 4 g/day)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adolescents &ge; 15 years: Oral: 250 to 1,000 mg every 6 hours; maximum daily dose: 4 g/day</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Indication-specific dosing:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Community-acquired pneumonia (CAP) (IDSA/PIDS 2011), <i>S. aureus</i> (methicillin-susceptible), mild infection or step-down therapy (preferred) (off-label use):</b> Infants &gt;3 months and Children: Oral: 75 to 100 mg/kg/day in 3 to 4 divided doses</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Cystitis, uncomplicated:</b> Adolescents &ge;15 years: Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Endocarditis, prophylaxis (dental, oral, or invasive respiratory tract procedures) (off-label use):</b> Infants, Children, and Adolescents: Oral: 50 mg/kg 30 to 60 minutes prior to procedure (maximum dose: 2 g). <b>Note:</b> American Heart Association (AHA) guidelines now recommend prophylaxis only in patients undergoing invasive procedures and in whom underlying cardiac conditions may predispose to a higher risk of adverse outcomes should infection occur (AHA [Wilson 2007]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Impetigo:</b> Children: Oral: 25 to 50 mg/kg/day in 3 to 4 divided doses; continue for 7 days, depending upon clinical response (IDSA [Stevens 2014])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Otitis media:</b> Children: 75 to 100 mg/kg/day in 4 divided doses</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Pharyngitis, streptococcal:</b> Children &gt;1 year: Oral: 25 to 50 mg/kg/day divided every 12 hours. <b>Note:</b> Recommended by the Infectious Disease Society of America (IDSA) as an alternative agent for group A streptococcal pharyngitis in penicillin-allergic patients (avoid in patients with immediate-type hypersensitivity to penicillin) at a dose of 40 mg/kg/day divided twice daily (maximum: 1000 mg daily) for 10 days (Shulman 2012).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Severe infections:</b> Children: Oral: 50 to 100 mg/kg/day in divided doses every 6 to 8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Skin and skin structure infections:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Manufacturer&rsquo;s labeling:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Children &gt;1 year and Adolescents &lt;15 years: Oral: 25 to 50 mg/kg/day in divided doses every 6 to 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Adolescents &ge;15 years: Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Alternate recommendations: Children: 25 to 50 mg/kg/day divided every 6 hours (IDSA [Stevens 2014])</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F148614\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F148615\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">Adolescents &gt;15 years and Adults:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl &ge;60 mL/minute: No dosage adjustment necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl 30 to 59 mL/minute: There are no specific dosage adjustments provided in the manufacturer&rsquo;s labeling; maximum recommended daily dose: 1,000 mg/day.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl 15 to 29 mL/minute: 250 mg every 8 to 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl 5 to 14 mL/minute (not yet on dialysis): 250 every 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl 1 to 4 mL/minute (not yet on dialysis): 250 mg every 48 to 60 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">End stage renal disease (ESRD) on intermittent hemodialysis: There are no dosage adjustments provided in the manufacturer&rsquo;s labeling; however the following guidelines have been used by some clinicians (Aronoff 2007): Oral: 250 to 500 mg every 12 to 24 hours; moderately dialyzable (20% to 50%); give dose after dialysis session.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Peritoneal dialysis: There are no dosage adjustments provided in the manufacturer&rsquo;s labeling; however, the following guidelines have been used by some clinicians (Aronoff 2007): Oral: 250 to 500 mg every 12 to 24 hours.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15682567\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F148585\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Capsule, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Daxbia: 333 mg [contains brilliant blue fcf (fd&amp;c blue #1), fd&amp;c yellow #10 (quinoline yellow), fd&amp;c yellow #6 (sunset yellow)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Keflex: 250 mg, 500 mg, 750 mg [contains brilliant blue fcf (fd&amp;c blue #1), fd&amp;c yellow #10 (quinoline yellow), fd&amp;c yellow #6 (sunset yellow)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 250 mg, 500 mg, 750 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Suspension Reconstituted, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 125 mg/5 mL (100 mL, 200 mL); 250 mg/5 mL (100 mL, 200 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 250 mg, 500 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F148569\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F148589\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Administer without regard to food. If GI distress, take with food. Give around-the-clock to promote less variation in peak and trough serum levels. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F148588\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Bone infections:</b> Treatment of bone infections caused by <i>Staphylococcus aureus</i> and/or <i>Proteus mirabilis</i>.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Genitourinary tract infections:</b> Treatment of genitourinary tract infections, including acute prostatitis, caused by <i>Escherichia coli</i>, <i>P. mirabilis</i>, and <i>Klebsiella pneumoniae</i>.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Otitis media:</b> Treatment of otitis media caused by <i>Streptococcus pneumoniae</i>, <i>Haemophilus influenzae</i>, <i>S. aureus</i>, <i>Streptococcus pyogenes</i>, and <i>Moraxella catarrhalis</i>. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Respiratory tract infections:</b> Treatment of respiratory tract infections caused by <i>S. pneumoniae</i> and <i>S. pyogenes</i>.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Skin and skin structure infections:</b> Treatment of skin and skin structure infections caused by <i>S. aureus</i> and/or <i>S. pyogenes</i>.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25475342\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Community-acquired pneumonia (children); Endocarditis, prophylaxis; Prosthetic joint infection</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F148636\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Cephalexin may be confused with cefaclor, ceFAZolin, ciprofloxacin</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Keflex may be confused with Keppra, Valtrex</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F148576\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">Frequency not defined. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Central nervous system: Agitation, confusion, dizziness, fatigue, hallucination, headache </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Dermatologic: Erythema multiforme (rare), genital pruritus, skin rash, Stevens-Johnson syndrome (rare), toxic epidermal necrolysis (rare), urticaria </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Gastrointestinal: Abdominal pain, diarrhea, dyspepsia, gastritis, nausea (rare), pseudomembranous colitis, vomiting (rare) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Genitourinary: Genital candidiasis, vaginal discharge, vaginitis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Hematologic &amp; oncologic: Eosinophilia, hemolytic anemia, neutropenia, thrombocytopenia </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Hepatic: Cholestatic jaundice (rare), hepatitis (transient, rare), increased serum ALT, increased serum AST</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Hypersensitivity: Anaphylaxis, angioedema, hypersensitivity reaction</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Neuromuscular &amp; skeletal: Arthralgia, arthritis, arthropathy</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Renal: Interstitial nephritis (rare) </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F148592\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to cephalexin, other cephalosporins, or any component of the formulation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F148573\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hypersensitivity: Allergic reactions (eg, rash, urticaria, angioedema,  anaphylaxis, erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis [TEN]) have been reported. If an allergic reaction occurs, discontinue immediately and institute appropriate treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Elevated INR: May be associated with increased INR, especially in nutritionally-deficient patients, prolonged treatment, hepatic or renal disease.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Penicillin allergy: Use with caution in patients with a history of penicillin allergy, especially IgE-mediated reactions (eg, anaphylaxis, angioedema, urticaria).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Seizure disorder:  Use with caution in patients with a history of seizure disorder; high levels, particularly in the presence of renal impairment, may increase risk of seizures.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Superinfection: Prolonged use may result in fungal or bacterial superinfection, including <i>C. difficile</i>-associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed &gt;2 months postantibiotic treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Renal impairment: Use with caution in patients with renal impairment; modify dosage in severe impairment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Direct Coombs tests:  Positive direct Coombs tests and acute intravascular hemolysis has been reported. If anemia develops during or after therapy, discontinue use and work up for drug-induced hemolytic anemia.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299003\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F148578\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9231&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Antibiotics may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG Vaccine (Immunization): Antibiotics may diminish the therapeutic effect of BCG Vaccine (Immunization). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cholera Vaccine: Antibiotics may diminish the therapeutic effect of Cholera Vaccine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lactobacillus and Estriol: Antibiotics may diminish the therapeutic effect of Lactobacillus and Estriol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MetFORMIN: Cephalexin may increase the serum concentration of MetFORMIN. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Multivitamins/Minerals (with ADEK, Folate, Iron): May decrease the serum concentration of Cephalexin. Specifically, the zinc contained in many multivitamins may decrease cephalexin absorption. Management: Consider administering multivitamins at least 3 hours after cephalexin.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Multivitamins/Minerals (with AE, No Iron): May decrease the serum concentration of Cephalexin. Specifically, the zinc contained in many multivitamins may decrease cephalexin absorption. Management: Consider administering multivitamins at least 3 hours after cephalexin.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Probenecid: May increase the serum concentration of Cephalosporins.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Vaccination with live attenuated typhoid vaccine (Ty21a) should be avoided in patients being treated with systemic antibacterial agents.  Use of this vaccine should be postponed until at least 3 days after cessation of antibacterial agents.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vitamin K Antagonists (eg, warfarin): Cephalosporins may enhance the anticoagulant effect of Vitamin K Antagonists. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Zinc Salts: May decrease the absorption of Cephalexin. Management: Consider administering oral zinc salts at least 3 hours after cephalexin.<b> Exceptions: </b>Zinc Chloride.<i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F148606\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:0em;display:inline\">Peak antibiotic serum concentration is lowered and delayed, but total drug absorbed is not affected. Cephalexin serum levels may be decreased if taken with food. Management: Administer without regard to food.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F148581\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">B (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3017197\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events were not observed in animal reproduction studies. Cephalexin crosses the placenta and produces therapeutic concentrations in the fetal circulation and amniotic fluid (Creatsas 1980). Peak concentrations in pregnant patients are similar to those in nonpregnant patients. Prolonged labor may decrease oral absorption (Griffith 1983; Paterson 1972).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F148595\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Cephalexin is excreted in breast milk.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">The relative infant dose (RID) of cephalexin is 0.13% to 0.52% when compared to an infant therapeutic dose of 25 to 100 mg/kg/day. In general, breastfeeding is considered acceptable when the relative infant dose is &lt;10%; when an RID is &gt;25% breastfeeding should generally be avoided (Anderson 2016; Ito 2000). Using a milk concentration of 0.85 mcg/mL, the estimated daily infant dose via breast milk is 0.13 mg/kg/day. This milk concentration was obtained following a single maternal dose of cephalexin 1,000 mg orally on the third postpartum day (Kafetzis 1981).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">The mean peak milk concentration occurred 4 to 5 hours after the dose (Kafetzis 1981). Slightly higher concentrations of cephalexin were detected in the breast milk of a lactating woman also administered probenecid and cephalexin for &ge;16 days (Ilett 2006).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Diarrhea has been reported in breastfeeding infants (Ilett 2006; Ito 1993). In general, antibiotics that are present in breast milk may cause nondose-related modification of bowel flora. Monitor infants for GI disturbances (WHO 2002).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">When an antibiotic is needed, cephalexin may be used to treat mastitis in breastfeeding women allergic to preferred agents (Amir 2014; Berens 2015). The manufacturer recommends that caution be exercised when administering cephalexin to nursing women.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F148583\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">With prolonged therapy monitor renal, hepatic, and hematologic function periodically; monitor for signs of anaphylaxis during first dose</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F148572\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Inhibits bacterial cell wall synthesis by binding to one or more of the penicillin-binding proteins (PBPs) which in turn inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell walls, thus inhibiting cell wall biosynthesis. Bacteria eventually lyse due to ongoing activity of cell wall autolytic enzymes (autolysins and murein hydrolases) while cell wall assembly is arrested.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F148591\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: Rapid (90%); delayed in young children and may be decreased up to 50% in neonates</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: Widely into most body tissues and fluids, including gallbladder, liver, kidneys, bone, sputum, bile, and pleural and synovial fluids; CSF penetration is poor</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: 6% to 15% </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: Neonates: 5 hours; Children 3-12 months: 2.5 hours; Adults: 0.5 to 1.2 hours (prolonged with renal impairment)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak, serum: ~1 hour</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine (80% to 100% as unchanged drug) within 8 hours</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F148594\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsules</b> (Cephalexin Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">250 mg (100): $69.35</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mg (500): $612.95</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">750 mg (50): $369.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsules</b> (Daxbia Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">333 mg (100): $1,140.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsules</b> (Keflex Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">250 mg (100): $1,043.10</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mg (100): $1,043.10</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">750 mg (50): $521.56</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Suspension (reconstituted)</b> (Cephalexin Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">125 mg/5 mL (100 mL): $23.75</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">250 mg/5 mL (100 mL): $28.75</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Cephalexin Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">250 mg (100): $418.33</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mg (100): $822.07</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F148597\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Acelex (BD);</li>\n      <li>Airex (PH);</li>\n      <li>Alexin (IN);</li>\n      <li>Arlexin (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Asef (BD);</li>\n      <li>Avloxin (BD);</li>\n      <li>Axcel (LK);</li>\n      <li>Bloflex (PH);</li>\n      <li>Capxin (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Cecan (PY);</li>\n      <li>Cefabiotic (ID);</li>\n      <li>Cefacet (FR);</li>\n      <li>Cefacin-M (HK);</li>\n      <li>Cefadal (BF, BJ, CI, ET, GH, GM, GN, KE, LR, MA, ML, MR, MU, MW, NE, NG, SC, SD, SL, SN, TN, TZ, UG, ZA, ZM, ZW);</li>\n      <li>Cefadin (EC);</li>\n      <li>Cefadyl (BF, BJ, CI, ET, GH, GM, GN, KE, LR, MA, ML, MR, MU, MW, NE, NG, SC, SD, SL, SN, TN, TZ, UG, ZM, ZW);</li>\n      <li>Cefalin (ID, PH);</li>\n      <li>Cefalver (MX);</li>\n      <li>Cefamor (ET, ZW);</li>\n      <li>Cefastad (HK);</li>\n      <li>Ceff (ET);</li>\n      <li>Ceforal (IL);</li>\n      <li>Cefovit (IL);</li>\n      <li>Cefrax (TR);</li>\n      <li>Celexin (ET);</li>\n      <li>Cephalen (SG);</li>\n      <li>Cephalex (DE);</li>\n      <li>Cephalexyl (TH);</li>\n      <li>Cephanmycin (MY, SG);</li>\n      <li>Cephast (ET);</li>\n      <li>Ceporex (AU, BB, BH, BM, BS, BZ, CR, CY, EG, GB, GT, GY, HN, IQ, IR, IT, JM, JO, KW, LB, LY, MX, NI, NZ, OM, PA, PH, PT, QA, SA, SR, SV, SY, TT, VN, YE, ZA);</li>\n      <li>Ceporex Forte (PT);</li>\n      <li>Ceporexin (AR);</li>\n      <li>Ceprax (CO);</li>\n      <li>Ceproex (DO);</li>\n      <li>Ceralin (HR);</li>\n      <li>Cerexin (ZA);</li>\n      <li>Cilex (AU);</li>\n      <li>Erocetin (PY, UY);</li>\n      <li>Falexin (KR);</li>\n      <li>Farmalex (TH);</li>\n      <li>Felexin (ET, LK, MY, TR);</li>\n      <li>Fexin (ZA);</li>\n      <li>Glexil (VN);</li>\n      <li>Glopixin (VN);</li>\n      <li>Ibilex (AU, NZ, TH);</li>\n      <li>Inphalex (ID);</li>\n      <li>Italcefal (EC);</li>\n      <li>Kefacin (BH, CY, EG, IQ, IR, JO, KR, KW, LB, LY, OM, QA, SA, SY, YE);</li>\n      <li>Kefalex (FI);</li>\n      <li>Kefalospes (GR);</li>\n      <li>Kefaxin (GR);</li>\n      <li>Keflex (AE, AT, BB, BF, BH, BJ, BM, BR, BS, BZ, CI, CO, CY, DK, EE, ET, GB, GH, GM, GN, GR, GY, IE, JM, JO, KE, KW, LB, LI, LR, MA, ML, MR, MU, MW, MX, NE, NG, NO, PE, PH, PK, PL, PT, QA, RO, SA, SC, SD, SE, SL, SN, SR, TH, TN, TT, TZ, UG, ZM, ZW);</li>\n      <li>Kefloridina (ES);</li>\n      <li>Keforal (AR, BE, FR, IT, NL, VE);</li>\n      <li>Kidolex (TW);</li>\n      <li>Larixin (JP);</li>\n      <li>LC-Lexin (PH);</li>\n      <li>Lecef (LK);</li>\n      <li>Lenocef (ZA);</li>\n      <li>Lexin (AE, BD, JO, PE, QA);</li>\n      <li>Lexipron (ID);</li>\n      <li>Madlexin (ID);</li>\n      <li>Meceta (VN);</li>\n      <li>Medolexin (MY);</li>\n      <li>Monocef (LI);</li>\n      <li>Nafacil-S (MX);</li>\n      <li>Neokef (MY);</li>\n      <li>Nufex (IN);</li>\n      <li>Oracef (CZ);</li>\n      <li>Oralexin (LB);</li>\n      <li>Oriphex (BF, BJ, CI, ET, GH, GM, GN, KE, LR, MA, ML, MR, MU, MW, NE, NG, SC, SD, SL, SN, TN, TZ, UG, ZM, ZW);</li>\n      <li>Ospeksyn (UA);</li>\n      <li>Ospexin (AT, BG, BH, CY, CZ, EG, IQ, IR, JO, KW, LB, LY, MY, OM, QA, SA, SY, YE);</li>\n      <li>Ospexina (CO);</li>\n      <li>Paferxin (MX);</li>\n      <li>Palitrex (ID);</li>\n      <li>Pectril (PH);</li>\n      <li>Pharmexin (BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);</li>\n      <li>Plecef (LK);</li>\n      <li>Proxicef (HR);</li>\n      <li>Ramoxin (JO);</li>\n      <li>Rancef (AU);</li>\n      <li>Relaxin (PH);</li>\n      <li>Sanaxin (AT);</li>\n      <li>Sef (LI);</li>\n      <li>SEF (TR);</li>\n      <li>Sepexin (IN);</li>\n      <li>Septilisin (AR);</li>\n      <li>Servicef (MX);</li>\n      <li>Servispor (TW);</li>\n      <li>Sialexin (TH);</li>\n      <li>Sofilex (HK, MY, SG);</li>\n      <li>Solulexin (MY);</li>\n      <li>Sorlex (PH);</li>\n      <li>Sporicef (TH);</li>\n      <li>Sporidex (AE, IN, PH);</li>\n      <li>Sporidin (TH);</li>\n      <li>Sporidin AF (TH);</li>\n      <li>Theoflex (LK);</li>\n      <li>Uphalexin (MY, SG);</li>\n      <li>Winlex (TW);</li>\n      <li>Zecef (LK)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    American Dental Association Council on Scientific Affairs, &ldquo;Combating Antibiotic Resistance,&rdquo; <i>J Am Dent Assoc</i>, 2004, 135(4):484-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cephalexin-drug-information/abstract-text/15127872 /pubmed\" target=\"_blank\" id=\"15127872 \">15127872 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"24911394\"></a>Amir LH, Academy of Breastfeeding Medicine Protocol Committee. ABM clinical protocol #4: Mastitis, revised March 2014. <i>Breastfeed Med</i>. 2014;9(5):239-243.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cephalexin-drug-information/abstract-text/24911394/pubmed\" target=\"_blank\" id=\"24911394\">24911394</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Anderson PO, Sauberan JB. Modeling drug passage into human milk. <i>Clin Pharmacol Ther</i>. 2016;100(1):42-52.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cephalexin-drug-information/abstract-text/27060684/pubmed\" target=\"_blank\" id=\"27060684\">27060684</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Aronoff GR, Bennett WM, Berns JS, et al. <i>Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children</i>, 5th ed. Philadelphia, PA: American College of Physicians; 2007.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Baddour LM. Impetigo. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed February 22, 2018.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Berbari E, Baddour LM. Prosthetic joint infection. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed February 22, 2018.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"26512442\"></a>Berens PD. Breast pain: engorgement, nipple pain, and mastitis. <i>Clin Obstet Gynecol</i>. 2015;58(4):902-914.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cephalexin-drug-information/abstract-text/26512442/pubmed\" target=\"_blank\" id=\"26512442\">26512442</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bergan T, &ldquo;Pharmacokinetic Properties of Cephalosporins,&rdquo; <i>Drugs</i>, 1987, 34 (Suppl 2):89-104.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cephalexin-drug-information/abstract-text/3319507/pubmed\" target=\"_blank\" id=\"3319507\">3319507</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bradley JS, Byington CL, Shah SS, et al. &ldquo;The Management of Community-Acquired Pneumonia in Infants and Children Older Than 3 Months of Age: Clinical Practice Guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America&rdquo;, <i>Clin Infect Dis</i>, 2011, 53(7):e25-76.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cephalexin-drug-information/abstract-text/21880587/pubmed\" target=\"_blank\" id=\"21880587\">21880587</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Creatsas G, Pavlatos M, Lolis D, Kaskarelis D. A study of the kinetics of cephapirin and cephalexin in pregnancy. <i>Curr Med Res Opin</i>. 1980;7(1):43-46.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cephalexin-drug-information/abstract-text/7428412/pubmed\" target=\"_blank\" id=\"7428412\">7428412</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dajani AS, Taubert KA, Wilson W, et al, &ldquo;Prevention of Bacterial Endocarditis Recommendations by the American Heart Association,&rdquo; <i>JAMA</i>, 1997, 277(22):1794-801.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cephalexin-drug-information/abstract-text/9178793/pubmed\" target=\"_blank\" id=\"9178793\">9178793</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Donowitz GR and Mandell GL, &ldquo;Beta-Lactam Antibiotics,&rdquo; <i>N Engl J Med</i>, 1988, 318(7):419-26 and 318(8):490-500.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cephalexin-drug-information/abstract-text/3277054/pubmed\" target=\"_blank\" id=\"3277054\">3277054</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Griffith RS. The pharmacology of cephalexin. <i>Postgrad Med J</i>. 1983;59(Suppl 5):16-27.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cephalexin-drug-information/abstract-text/6364086/pubmed\" target=\"_blank\" id=\"6364086\">6364086</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hooton TM, Gupta K. Acute uncomplicated cystitis in women. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed February 22, 2018.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"16551765\"></a>Ilett KF, Hackett LP, Ingle B, Bretz PJ. Transfer of probenecid and cephalexin into breast milk. <i>Ann Pharmacother</i>. 2006;40(5):986-989.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cephalexin-drug-information/abstract-text/16551765/pubmed\" target=\"_blank\" id=\"16551765\">16551765</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"8498418\"></a>Ito S, Blajchman A, Stephenson M, Eliopoulos C, Koren G. Prospective follow-up of adverse reactions in breast-fed infants exposed to maternal medication. <i>Am J Obstet Gynecol</i>. 1993;168(5):1393-1399.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cephalexin-drug-information/abstract-text/8498418/pubmed\" target=\"_blank\" id=\"8498418\">8498418</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ito S. Drug therapy for breast-feeding women. <i>N Engl J Med</i>. 2000;343(2):118-126.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cephalexin-drug-information/abstract-text/10891521/pubmed\" target=\"_blank\" id=\"10891521\">10891521</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Jevsevar DS and Abt E, &quot;The New AAOS-ADA Clinical Practice Guideline on Prevention of Orthopaedic Implant Infection in Patients Undergoing Dental Procedures,&quot; <i>J Am Acad Orthop Surg</i>, 2013, 21(3):195-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cephalexin-drug-information/abstract-text/23457071/pubmed\" target=\"_blank\" id=\"23457071\">23457071</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kafetzis DA, Siafas CA, Georgakopoulos PA, Papadatos CJ. Passage of cephalosporins and amoxicillin into the breast milk. <i>Acta Paediatr Scand</i>. 1981;70(3):285-288.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cephalexin-drug-information/abstract-text/7246123/pubmed\" target=\"_blank\" id=\"7246123\">7246123</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kanafani ZA. Invasive Cutibacterium (formerly Propionibacterium) infections. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed February 22, 2018.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Keflex (cephalexin) capsules [prescribing information]. Florham Park, NJ: Shionogi; October 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lipsky BA, Berendt AR, Cornia PB, et al, &quot;2012 Infectious Diseases Society of America Clinical Practice Guideline for the Diagnosis and Treatment of Diabetic Foot Infections,&quot; <i>Clin Infect Dis</i>, 2012, 54(12):e132-73.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cephalexin-drug-information/abstract-text/22619242/pubmed\" target=\"_blank\" id=\"22619242\">22619242</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Osmon DR, Berbari EF, Berendt AR, et al, &ldquo;Diagnosis and Management of Prosthetic Joint Infection: Clinical Practice Guideline by the Infectious Diseases Society of America,&rdquo; <i>Clin Infect Dis</i>, 2013, 56(1):e1-25.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cephalexin-drug-information/abstract-text/23223583/pubmed\" target=\"_blank\" id=\"23223583\">23223583</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Paterson ML, Henderson A, Lunan CB, et al, &quot;Transplacental Transfer of Cephalexin,&quot; <i>Clinical Medicine</i>, 1972, 22-4.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Saxon A, Beall GN, Rohr AS, et al, &ldquo;Immediate Hypersensitivity Reactions to Beta-Lactam Antibiotics,&rdquo; <i>Ann Intern Med</i>, 1987, 107(2):204-15.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cephalexin-drug-information/abstract-text/3300459/pubmed\" target=\"_blank\" id=\"3300459\">3300459</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shulman ST, Bisno AL, Clegg HW, et al, &ldquo;Clinical Practice Guideline for the Diagnosis and Management of Group A Streptococcal Pharyngitis: 2012 Update by the Infectious Diseases Society of America,&rdquo; <i>Clin Infect Dis</i>, 2012, 55(10):e86-102.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cephalexin-drug-information/abstract-text/22965026/pubmed\" target=\"_blank\" id=\"22965026\">22965026</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Smith GH, &ldquo;Oral Cephalosporins in Perspective,&rdquo; <i>DICP</i>, 1990, 24(1):45-51.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cephalexin-drug-information/abstract-text/2405586/pubmed\" target=\"_blank\" id=\"2405586\">2405586</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sollecito TP, Abt E, Lockhart PB, et al. The use of prophylactic antibiotics prior to dental procedures in patients with prosthetic joints: Evidence-based clinical practice guideline for dental practitioners--a report of the American Dental Association Council on Scientific Affairs. <i>J Am Dent Assoc.</i> 2015; 146(1):11-16.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cephalexin-drug-information/abstract-text/25569493/pubmed\" target=\"_blank\" id=\"25569493\">25569493</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America. <i>Clin Infect Dis</i>. 2014;59(2):e10-e52.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cephalexin-drug-information/abstract-text/24973422/pubmed\" target=\"_blank\" id=\"24973422\">24973422</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"25124380\"></a>Terico AT, Gallagher JC. Beta-lactams hypersensitivity and cross-reactivity. <i>J Pharm Pract</i>. 2014;27(6):530-544.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cephalexin-drug-information/abstract-text/25124380/pubmed\" target=\"_blank\" id=\"25124380\">25124380</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wilson W, Taubert KA, Gewitz M, et al, &ldquo;Prevention of Infective Endocarditis. Guidelines From the American Heart Association. A Guideline From the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee, Council on Cardiovascular Disease in the Young, and the Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and the Quality of Care and Outcomes Research Interdisciplinary Working Group,&rdquo; <i>Circulation</i>, 2007, 115.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cephalexin-drug-information/abstract-text/17446442/pubmed\" target=\"_blank\" id=\"17446442\">17446442</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    World Health Organization (WHO). Breastfeeding and maternal medication, recommendations for drugs in the eleventh WHO model list of essential drugs. 2002. Available at http://www.who.int/maternal_child_adolescent/documents/55732/en/</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wynn RL, Bergman SA, Meiller TF, et al, &ldquo;Antibiotics in Treating Oral-Facial Infections of Odontogenic Origin: An Update,&rdquo; <i>Gen Dent</i>, 2001, 49(3):238-40, 242, 244 passim.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cephalexin-drug-information/abstract-text/12004720 /pubmed\" target=\"_blank\" id=\"12004720 \">12004720 </a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9231 Version 225.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F148610\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F148611\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F148629\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F148613\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F148624\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F148614\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F148615\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F15682567\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F148585\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F148569\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F148589\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F148588\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25475342\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F148636\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F148576\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F148592\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F148573\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299003\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F148578\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F148606\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F148581\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F3017197\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F148595\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F148583\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F148572\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F148591\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F148594\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F148597\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9231|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=cephalexin-patient-drug-information\" class=\"drug drug_patient\">Cephalexin: Patient drug information</a></li><li><a href=\"topic.htm?path=cephalexin-pediatric-drug-information\" class=\"drug drug_pediatric\">Cephalexin: Pediatric drug information</a></li></ul></div></div>","javascript":null}